Quarterly ResultMay 7, 2026, 04:14 PM
Rocket Pharma Q1 Net Loss $(47.6)M; KRESLADI™ FDA Approved; $180M PRV Sale
AI Summary
Rocket Pharmaceuticals reported a reduced net loss of $(47.6) million for Q1 2026, down from $(61.3) million in Q1 2025. The company received FDA accelerated approval for KRESLADI™ in March 2026 for severe LAD-I, though material revenue is not expected in the near term. To support its cardiovascular gene therapy pipeline and extend its operational runway, Rocket entered an agreement in April 2026 to sell its Rare Pediatric Disease Priority Review Voucher for $180 million. The company also implemented a strategic reorganization in July 2025, reducing its workforce by 30% to focus on its AAV-based gene therapy platform.
Key Highlights
- KRESLADI™ received FDA accelerated approval in March 2026 for severe LAD-I.
- Net loss for Q1 2026 was $(47.6) million, a reduction from $(61.3) million in Q1 2025.
- Net loss per share for Q1 2026 was $(0.42), improved from $(0.56) in Q1 2025.
- Entered agreement in April 2026 to sell Rare Pediatric Disease PRV for $180 million.
- Cash, cash equivalents, and investments totaled $144.4 million as of March 31, 2026.
- Net cash used in operating activities decreased to $(45.4) million in Q1 2026.
- Implemented a strategic corporate reorganization in July 2025, reducing workforce by 30%.